La Jolla Pharmaceutical Co.
(NASDAQ : LJPC)

( )
LJPC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -0.35%62.981.0%$459.39m
AMGNAmgen, Inc. 0.41%241.491.3%$450.37m
BIIBBiogen, Inc. -0.22%285.501.4%$388.18m
ILMNIllumina, Inc. -0.38%324.723.5%$319.30m
VRTXVertex Pharmaceuticals, Inc. 0.14%235.831.9%$300.51m
REGNRegeneron Pharmaceuticals, Inc. 0.10%385.942.6%$230.09m
EXASEXACT Sciences Corp. -1.92%88.0624.0%$200.47m
ALXNAlexion Pharmaceuticals, Inc. 0.68%113.272.0%$195.19m
ITCIIntra-Cellular Therapies, Inc. -1.43%26.259.0%$173.29m
INCYIncyte Corp. -0.15%80.502.5%$149.14m
SRPTSarepta Therapeutics, Inc. -1.84%127.9014.6%$142.47m
ARWRArrowhead Pharmaceuticals, Inc. -1.21%56.4211.4%$131.86m
SGENSeattle Genetics, Inc. 1.25%109.006.1%$126.99m
BMRNBioMarin Pharmaceutical, Inc. -0.97%88.274.3%$108.23m
AAgilent Technologies, Inc. 0.79%90.171.6%$106.55m

Company Profile

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla's investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA.